RPRX vs RCUS vs OR vs WPM vs RGLD

For growth investors, Wheaton Precious Metals Corp.

(WPM) is the stronger pick with 83. 3% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Royalty Pharma plc (RPRX) offers the better valuation at 27. 9x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Royalty Pharma plc (RPRX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Royalty Pharma plc (RPRX) is the cheapest at 27.

9x versus Wheaton Precious Metals Corp. at 40. 0x. On forward P/E, Royalty Pharma plc is actually cheaper at 10. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: OR Royalties Inc. wins at 0. 30x versus Royal Gold, Inc. 's 2. 51x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Wheaton Precious Metals Corp.

(WPM) delivered a total return of +207. 9%, compared to -18. 6% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: WPM returned +649. 6% versus RPRX's +22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Royalty Pharma plc (RPRX) is the lower-risk stock at 0.

45β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 330% more volatile than RPRX relative to the S&P 500. On balance sheet safety, Wheaton Precious Metals Corp. (WPM) carries a lower debt/equity ratio of 0% versus 92% for Royalty Pharma plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Wheaton Precious Metals Corp.

(WPM) is pulling ahead at 83. 3% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: OR Royalties Inc. grew EPS 825. 0% year-over-year, compared to -5. 8% for Royalty Pharma plc. Over a 3-year CAGR, WPM leads at 30. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OR Royalties Inc.

(OR) is the more profitable company, earning 74. 3% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 74. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OR leads at 72. 9% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RPRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, OR Royalties Inc. (OR) is the more undervalued stock at a PEG of 0. 30x versus Royal Gold, Inc. 's 2. 51x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Royalty Pharma plc (RPRX) trades at 10. 3x forward P/E versus 24. 2x for Wheaton Precious Metals Corp. — 14. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RGLD: 31. 0% to $304. 80.

In this comparison, RPRX (1.

3% yield), RGLD (0. 7% yield), WPM (0. 5% yield), OR (0. 5% yield) pay a dividend. RCUS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Wheaton Precious Metals Corp.

(WPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), 0. 5% yield, +649. 6% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WPM: +649. 6%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RPRX (Healthcare) and RCUS (Healthcare) and OR (Basic Materials) and WPM (Basic Materials) and RGLD (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RPRX is a mid-cap quality compounder stock; RCUS is a small-cap quality compounder stock; OR is a small-cap high-growth stock; WPM is a mid-cap high-growth stock; RGLD is a mid-cap high-growth stock. RPRX, OR, WPM, RGLD pay a dividend while RCUS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.